This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Solid Tumor
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
Gimatecan® is sigma-tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in this
class play a crucial role in destroying DNA replication in tumors. We are conducting this
study to determine the Maximum Tolerated Dose of our compound, when given as a capsule,
rather than by intravenous injection.
Phase:
Phase 1
Details
Lead Sponsor:
Sigma-Tau Research, Inc.
Collaborators:
Dana-Farber Cancer Institute Rhode Island Hospital